A Clinical Radiomics Nomogram Was Developed by Integrating Radiomics Signatures and Clinical Variables to Distinguish High-Grade ccRCC from Type 2 pRCC

Table 2

Clinical factors in the training cohort and testing cohort.

Clinical factors	Training cohort (n = 98)			Testing cohort (n = 44)
	ccRCC	pRCC		ccRCC	pRCC
Gender			0.628			0.296
Male	39 (80%)	37 (76%)		15 (68%)	18 (82%)
Female	10 (20%)	12 (24%)		7 (32%)	4 (18%)
Age (years)	61 (54–65)	57 (51–67)	0.719	54 (50–66)	61 (55–71)	0.208
Maximum diameter (cm)	6.8 (4.7–8.9)	6.1 (4.5–7.5)	0.216	6.4 (4.1–8.3)	5.5 (3.4–7.5)	0.291
Shape			0.225			0.066
Round	23 (47%)	26 (53%)		6	12
Not round	26 (53%)	23 (47%)		16	10
Location			0.417			0.226
Left	25 (51%)	29 (59%)		8 (36%)	12 (55%)
Right	24 (49%)	20 (41%)		14 (64%)	10 (45%)
Boundary			0.065			0.033
Clear	16 (33%)	25 (51%)		6 (27%)	13 (59%)
Blurred	33 (67%)	24 (49%)		16 (73%)	9 (41%)
Calcification			0.258			0.240
Present	11 (22%)	16 (33%)		2 (9%)	6 (27%)
Absent	38 (78%)	33 (67%)		20 (91%)	16 (73%)
Necrosis			0.051			0.531
Present	38 (78%)	20 (41%)		15 (68%)	13 (59%)
Absent	11 (22%)	29 (59%)		7 (32%)	9 (41%)
Renal vein invasion			0.798			0.750
Present	10 (20%)	9 (18%)		8 (36%)	7 (32%)
Absent	39 (80%)	40 (82%)		14 (64%)	15 (62%)
Lymph node metastasis			0.647			0.757
Present	14 (29%)	12 (24%)		9 (41%)	8 (36%)
Absent	35 (71%)	37 (76%)		13 (59%)	14 (64%)
TEV1 (HU)	70 (48–84)	22 (17–34)	<0.001	59 (26–112)	15 (9–19)	<0.001
TEV2 (HU)	72 (58–83)	40 (26–57)	<0.001	81 (53–104)	27 (19–37)	<0.001
REV1	0.77 (0.58–0.91)	0.25 (0.17–0.38)	<0.001	0.64 (0.29–0.95)	0.17 (0.11–0.27)	<0.001
REV2	0.60 (0.50–0.73)	0.31 (0.22–0.49)	<0.001	0.65 (0.52–0.76)	0.26 (0.18–0.36)	<0.001

TEV, tumor enhancement value; REV, relative enhancement value; 1, corticomedullary phase; 2, nephrographic phase.